Top

Published in:

Open Access 12-08-2023 | Gastric Cancer | Original Article

PPARδ dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment

Authors: Yi Liu, Daoyan Wei, Yasunori Deguchi, Weiguo Xu, Rui Tian, Fuyao Liu, Min Xu, Fei Mao, Donghui Li, Weidong Chen, Lovie Ann Valentin, Eriko Deguchi, James C. Yao, Imad Shureiqi, Xiangsheng Zuo

Published in: Gastric Cancer | Issue 6/2023

Abstract

Background

Peroxisome proliferator-activated receptor delta (PPARδ) promotes inflammation and carcinogenesis in many organs, but the underlying mechanisms remains elusive. In stomachs, PPARδ significantly increases chemokine Ccl20 expression in gastric epithelial cells while inducing gastric adenocarcinoma (GAC). CCR6 is the sole receptor of CCL20. Here, we examine the role of PPARδ–mediated Ccl20/Ccr6 signaling in GAC carcinogenesis and investigate the underlying mechanisms.

Methods

The effects of PPARδ inhibition by its specific antagonist GSK3787 on GAC were examined in the mice with villin-promoter–driven PPARδ overexpression (Ppard^TG). RNAscope Duplex Assays were used to measure Ccl20 and Ccr6 levels in stomachs and spleens. Subsets of stomach-infiltrating immune cells were measured via flow cytometry or immunostaining in Ppard^TG mice fed GSK3787 or control diet. A panel of 13 optimized proinflammatory chemokines in mouse sera were quantified by an enzyme-linked immunosorbent assay.

Results

GSK3787 significantly suppressed GAC carcinogenesis in Ppard^TG mice. PPARδ increased Ccl20 level to chemoattract Ccr6⁺ immunosuppressive cells, including tumor-associated macrophages, myeloid-derived suppressor cells and T regulatory cells, but decreased CD8⁺ T cells in gastric tissues. GSK3787 suppressed PPARδ–induced gastric immunosuppression by inhibiting Ccl20/Ccr6 axis. Furthermore, Ccl20 protein levels increased in sera of Ppard^TG mice starting at the age preceding gastric tumor development and further increased with GAC progression as the mice aged. GSK3787 decreased the PPARδ-upregulated Ccl20 levels in sera of the mice.

Conclusions

PPARδ dysregulation of Ccl20/Ccr6 axis promotes GAC carcinogenesis by remodeling gastric tumor microenvironment. CCL20 might be a potential biomarker for the early detection and progression of GAC.

Available only for authorised users

Casamayor M, Morlock R, Maeda H, Ajani J. Targeted literature review of the global burden of gastric cancer. Ecancermedicalscience. 2018;12:883. https://doi.org/10.3332/ecancer.2018.883.CrossRefPubMedPubMedCentral

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Neels JG, Grimaldi PA. Physiological functions of peroxisome proliferator-activated receptor beta. Physiol Rev. 2014;94(3):795–858. https://doi.org/10.1152/physrev.00027.2013.CrossRefPubMed

Manickam R, Wahli W. Roles of peroxisome proliferator-activated receptor beta/delta in skeletal muscle physiology. Biochimie. 2017;136:42–8. https://doi.org/10.1016/j.biochi.2016.11.010.CrossRefPubMed

Wang D, Fu L, Ning W, Guo L, Sun X, Dey SK, et al. Peroxisome proliferator-activated receptor δ promotes colonic inflammation and tumor growth. Proc Natl Acad Sci U S A. 2014;111(19):7084–9. https://doi.org/10.1073/pnas.1324233111.CrossRefPubMedPubMedCentral

Montagner A, Delgado MB, Tallichet-Blanc C, Chan JS, Sng MK, Mottaz H, et al. Src is activated by the nuclear receptor peroxisome proliferator-activated receptor β/δ in ultraviolet radiation-induced skin cancer. EMBO Mol Med. 2014;6(1):80–98. https://doi.org/10.1002/emmm.201302666.CrossRefPubMed

Xu M, Zuo X, Shureiqi I. Targeting peroxisome proliferator-activated receptor-beta/delta in colon cancer: how to aim? Biochem Pharmacol. 2013;85(5):607–11. https://doi.org/10.1016/j.bcp.2012.09.031.CrossRefPubMed

Zuo X, Deguchi Y, Xu W, Liu Y, Li HS, Wei D, et al. PPARD and interferon gamma promote transformation of gastric progenitor cells and tumorigenesis in mice. Gastroenterology. 2019. https://doi.org/10.1053/j.gastro.2019.03.018.CrossRefPubMed

Wagner N, Wagner KD. PPAR beta/delta and the hallmarks of cancer. Cells. 2020. https://doi.org/10.3390/cells9051133.CrossRefPubMedPubMedCentral

10.

Liu Y, Colby JK, Zuo X, Jaoude J, Wei D, Shureiqi I. The role of PPAR-δ in metabolism, inflammation, and cancer: many characters of a critical transcription factor. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19113339.CrossRefPubMedPubMedCentral

11.

Qiao XT, Ziel JW, McKimpson W, Madison BB, Todisco A, Merchant JL, et al. Prospective identification of a multilineage progenitor in murine stomach epithelium. Gastroenterology. 2007;133(6):1989–98. https://doi.org/10.1053/j.gastro.2007.09.031.CrossRefPubMed

12.

Ma ES, Wang ZX, Zhu MQ, Zhao J. Immune evasion mechanisms and therapeutic strategies in gastric cancer. World J Gastrointest Oncol. 2022;14(1):216–29. https://doi.org/10.4251/wjgo.v14.i1.216.CrossRefPubMedPubMedCentral

13.

Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41. https://doi.org/10.1016/j.immuni.2019.06.025.CrossRefPubMedPubMedCentral

14.

Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482–92. https://doi.org/10.1093/annonc/mdw168.CrossRefPubMed

15.

Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, et al. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell. 2019;35(4):559-72.e7. https://doi.org/10.1016/j.ccell.2019.02.008.CrossRefPubMedPubMedCentral

16.

Hou P, Kapoor A, Zhang Q, Li J, Wu CJ, Li J, et al. Tumor microenvironment remodeling enables bypass of oncogenic KRAS dependency in pancreatic cancer. Cancer Discov. 2020;10(7):1058–77. https://doi.org/10.1158/2159-8290.Cd-19-0597.CrossRefPubMedPubMedCentral

17.

Fan Y, Li Y, Yao X, Jin J, Scott A, Liu B, et al. Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment. Gut. 2022. https://doi.org/10.1136/gutjnl-2021-326581.CrossRefPubMed

18.

Kim W, Chu TH, Nienhüser H, Jiang Z, Del Portillo A, Remotti HE, et al. PD-1 signaling promotes tumor-infiltrating myeloid-derived suppressor cells and gastric tumorigenesis in mice. Gastroenterology. 2021;160(3):781–96. https://doi.org/10.1053/j.gastro.2020.10.036.CrossRefPubMed

19.

Lee AY, Eri R, Lyons AB, Grimm MC, Korner H. CC chemokine ligand 20 and its cognate receptor CCR6 in mucosal T cell immunology and inflammatory bowel disease: odd couple or axis of evil? Front Immunol. 2013;4:194. https://doi.org/10.3389/fimmu.2013.00194.CrossRefPubMedPubMedCentral

20.

Kadomoto S, Izumi K, Mizokami A. The CCL20-CCR6 axis in cancer progression. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21155186.CrossRefPubMedPubMedCentral

21.

Chen W, Qin Y, Liu S. CCL20 signaling in the tumor microenvironment. Adv Exp Med Biol. 2020;1231:53–65. https://doi.org/10.1007/978-3-030-36667-4_6.CrossRefPubMed

22.

Zuo X, Xu M, Yu J, Wu Y, Moussalli MJ, Manyam GC, et al. Potentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-delta/beta overexpression. J Natl Cancer Inst. 2014;106(4):dju052. https://doi.org/10.1093/jnci/dju052.CrossRefPubMedPubMedCentral

23.

Szász AM, Lánczky A, Nagy Á, Förster S, Hark K, Green JE, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016;7(31):49322–33. https://doi.org/10.18632/oncotarget.10337.CrossRefPubMedPubMedCentral

24.

Palkar PS, Borland MG, Naruhn S, Ferry CH, Lee C, Sk UH, et al. Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787. Mol Pharmacol. 2010;78(3):419–30. https://doi.org/10.1124/mol.110.065508.CrossRefPubMedPubMedCentral

25.

Han G, Wu D, Yang Y, Li Z, Zhang J, Li C. CrkL meditates CCL20/CCR6-induced EMT in gastric cancer. Cytokine. 2015;76(2):163–9. https://doi.org/10.1016/j.cyto.2015.05.009.CrossRefPubMed

26.

Zhang X, Ni Z, Duan Z, Xin Z, Wang H, Tan J, et al. Overexpression of E2F mRNAs associated with gastric cancer progression identified by the transcription factor and miRNA co-regulatory network analysis. PLoS ONE. 2015;10(2):e0116979. https://doi.org/10.1371/journal.pone.0116979.CrossRefPubMedPubMedCentral

27.

Pollock CB, Rodriguez O, Martin PL, Albanese C, Li X, Kopelovich L, et al. Induction of metastatic gastric cancer by peroxisome proliferator-activated receptordelta activation. PPAR Res. 2010;2010:571783. https://doi.org/10.1155/2010/571783.CrossRefPubMedPubMedCentral

28.

Song S, Wang Z, Li Y, Ma L, Jin J, Scott AW, et al. PPARδ interacts with the hippo coactivator YAP1 to promote SOX9 expression and gastric cancer progression. Mol Cancer Res MCR. 2020;18(3):390–402. https://doi.org/10.1158/1541-7786.Mcr-19-0895.CrossRefPubMed

29.

Vogiatzi P, Cassone M, Luzzi I, Lucchetti C, Otvos L Jr, Giordano A. Helicobacter pylori as a class I carcinogen: physiopathology and management strategies. J Cell Biochem. 2007;102(2):264–73. https://doi.org/10.1002/jcb.21375.CrossRefPubMed

30.

Palrasu M, Zaika E, El-Rifai W, Garcia-Buitrago M, Piazuelo MB, Wilson KT, et al. Bacterial CagA protein compromises tumor suppressor mechanisms in gastric epithelial cells. J Clin Invest. 2020;130(5):2422–34. https://doi.org/10.1172/jci130015.CrossRefPubMedPubMedCentral

31.

Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784–9. https://doi.org/10.1056/NEJMoa001999.CrossRefPubMed

32.

Mera RM, Bravo LE, Camargo MC, Bravo JC, Delgado AG, Romero-Gallo J, et al. Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. Gut. 2018;67(7):1239–46. https://doi.org/10.1136/gutjnl-2016-311685.CrossRefPubMed

33.

Khatoon J, Rai RP, Prasad KN. Role of Helicobacter pylori in gastric cancer: updates. World J Gastrointest Oncol. 2016;8(2):147–58. https://doi.org/10.4251/wjgo.v8.i2.147.CrossRefPubMedPubMedCentral

34.

Sigal M, Rothenberg ME, Logan CY, Lee JY, Honaker RW, Cooper RL, et al. Helicobacter pylori activates and expands Lgr5(+) stem cells through direct colonization of the gastric glands. Gastroenterology. 2015;148(7):1392-404.e21. https://doi.org/10.1053/j.gastro.2015.02.049.CrossRefPubMed

35.

Liabeuf D, Oshima M, Stange DE, Sigal M. Stem Cells, Helicobacter pylori, and mutational landscape: utility of preclinical models to understand carcinogenesis and to direct management of gastric cancer. Gastroenterology. 2022;162(4):1067–87. https://doi.org/10.1053/j.gastro.2021.12.252.CrossRefPubMed

36.

Nagy TA, Wroblewski LE, Wang D, Piazuelo MB, Delgado A, Romero-Gallo J, et al. beta-Catenin and p120 mediate PPARdelta-dependent proliferation induced by Helicobacter pylori in human and rodent epithelia. Gastroenterology. 2011;141(2):553–64. https://doi.org/10.1053/j.gastro.2011.05.004.CrossRefPubMed

37.

Wang K, Shen T, Siegal GP, Wei S. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer. Hum Pathol. 2017;69:110–7. https://doi.org/10.1016/j.humpath.2017.09.012.CrossRefPubMed

38.

Zurlo IV, Schino M, Strippoli A, Calegari MA, Cocomazzi A, Cassano A, et al. Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. Cancer Immunol Immunother. 2022;71(1):45–55. https://doi.org/10.1007/s00262-021-02960-1.CrossRefPubMed

39.

Lee PH, Yang TY, Chen KC, Huang YH, Tseng JS, Hsu KH, et al. Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors. Sci Rep. 2021;11(1):9381. https://doi.org/10.1038/s41598-021-89043-4.CrossRefPubMedPubMedCentral

40.

Liu Y, Deguchi Y, Wei D, Liu F, Moussalli MJ, Deguchi E, et al. Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ. Nat Commun. 2022;13(1):2665. https://doi.org/10.1038/s41467-022-30392-7.CrossRefPubMedPubMedCentral

41.

Abrego J, Sanford-Crane H, Oon C, Xiao X, Betts CB, Sun D, et al. A cancer cell-intrinsic GOT2-PPARδ axis suppresses antitumor immunity. Cancer Discov. 2022;12(10):2414–33. https://doi.org/10.1158/2159-8290.Cd-22-0661.CrossRefPubMedPubMedCentral

42.

Necula L, Matei L, Dragu D, Neagu AI, Mambet C, Nedeianu S, et al. Recent advances in gastric cancer early diagnosis. World J Gastroenterol. 2019;25(17):2029–44. https://doi.org/10.3748/wjg.v25.i17.2029.CrossRefPubMedPubMedCentral

43.

Camargo MC, Song M, Sawada N, Inoue M, Shimazu T, Charvat H, et al. Prediagnostic circulating inflammation-related biomarkers and gastric cancer: a case-cohort study in Japan. Cytokine. 2021;144:155558. https://doi.org/10.1016/j.cyto.2021.155558.CrossRefPubMed

44.

Shen Q, Polom K, Williams C, de Oliveira FMS, Guergova-Kuras M, Lisacek F, et al. A targeted proteomics approach reveals a serum protein signature as diagnostic biomarker for resectable gastric cancer. EBioMedicine. 2019;44:322–33. https://doi.org/10.1016/j.ebiom.2019.05.044.CrossRefPubMedPubMedCentral

45.

Song M, Rabkin CS, Torres J, Kemp TJ, Zabaleta J, Pinto LA, et al. Circulating inflammation-related markers and advanced gastric premalignant lesions. J Gastroenterol Hepatol. 2019;34(5):852–6. https://doi.org/10.1111/jgh.14518.CrossRefPubMed

Title: PPARδ dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment
Authors: Yi Liu
Daoyan Wei
Yasunori Deguchi
Weiguo Xu
Rui Tian
Fuyao Liu
Min Xu
Fei Mao
Donghui Li
Weidong Chen
Lovie Ann Valentin
Eriko Deguchi
James C. Yao
Imad Shureiqi
Xiangsheng Zuo
Publication date: 12-08-2023
Publisher: Springer Nature Singapore
Keywords: Gastric Cancer
Gastric Cancer
Biomarkers
Published in: Gastric Cancer / Issue 6/2023
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI: https://doi.org/10.1007/s10120-023-01418-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2023

Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study

Acknowledgment to Reviewers

Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience

LncRNA expression signature identified using genome-wide transcriptomic profiling to predict lymph node metastasis in patients with stage T1 and T2 gastric cancer

Collagen-related gene expression level predicts the prognosis and immune therapy response

Prognostic value of post-operative serum procalcitonin in gastric adenocarcinoma patients undergoing radical gastrectomy: propensity score matching analysis of extended cohort from a prospective bi-center study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials